Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CMPX Stock Summary
Top 10 Correlated ETFs
CMPX
In the News
3 Penny Stocks With the Power to 10X Your $1K Investment
Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Compass Therapeutics, Inc. (CMPX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which is taking place at the Lotte New York Palace November 29 – December 1, 2022.
Compass Therapeutics to Present at Upcoming Investment Conferences
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during the month of November 2022.
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place in New York City September 12 – 14, 2022.
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, is presenting virtually at the 2022 H.C. Wainwright Global Investment Conference, occurring May 23-26th, 2022.
Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009
Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics, Inc. (Nasdaq: CMPX) will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wed., Jan. 12, 2022.
Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
CMPX Financial details
CMPX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.73 | -0.67 | -0.96 | -1.31 | -0.35 | |
Operating cash flow per share | -0.65 | -0.61 | -0.87 | -0.31 | -0.32 | |
Free cash flow per share | -0.69 | -0.62 | -0.87 | -0.34 | -0.33 | |
Cash per share | 1.1 | 0.49 | 1.53 | 2.3 | 1.77 | |
Book value per share | -1.63 | -2.28 | 1.3 | 2.23 | 1.73 | |
Tangible book value per share | -1.63 | -2.28 | 1.3 | 2.23 | 1.73 | |
Share holders equity per share | -1.63 | -2.28 | 1.3 | 2.23 | 1.73 | |
Interest debt per share | 0.3 | 0.31 | 0.33 | 0.07 | 0.05 | |
Market cap | 442.95M | 442.95M | 261.6M | 199.3M | 529.09M | |
Enterprise value | 400.19M | 432.52M | 223.85M | 58.82M | 497.07M | |
P/E ratio | -11.57 | -12.75 | -8.87 | -2.41 | -14.38 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -13.15 | -13.96 | -9.76 | -10.13 | -15.5 | |
PFCF ratio | -12.41 | -13.75 | -9.72 | -9.39 | -15.41 | |
P/B Ratio | -5.23 | -3.73 | 6.55 | 1.42 | 2.91 | |
PTB ratio | -5.23 | -3.73 | 6.55 | 1.42 | 2.91 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -11.2 | -13.87 | -8.84 | -1.99 | -13.29 | |
EV to operating cash flow | -11.88 | -13.63 | -8.35 | -2.99 | -14.57 | |
EV to free cash flow | -11.21 | -13.43 | -8.32 | -2.77 | -14.48 | |
Earnings yield | -0.09 | -0.08 | -0.11 | -0.41 | -0.07 | |
Free cash flow yield | -0.08 | -0.07 | -0.1 | -0.11 | -0.06 | |
Debt to equity | -0.17 | -0.13 | 0.23 | 0.03 | 0.02 | |
Debt to assets | 0.23 | 0.49 | 0.18 | 0.03 | 0.01 | |
Net debt to EBITDA | 1.2 | 0.33 | 1.49 | 4.74 | 0.86 | |
Current ratio | 6.96 | 2.67 | 4.97 | 13.84 | 12.05 | |
Interest coverage | -49.95 | -27.73 | -30.63 | -221.3 | -17.65 | |
Income quality | 0.88 | 0.91 | 0.91 | 0.24 | 0.87 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.06 | 0.01 | 0 | 0.08 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.05 | -0.22 | -0.04 | -0.97 | -0.11 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.19 | 5.84 | 5.29 | 8.11 | 3.69 | |
ROIC | 0.55 | 0.33 | -0.56 | -0.56 | -0.21 | |
Return on tangible assets | -0.59 | -1.14 | -0.57 | -0.54 | -0.18 | |
Graham Net | -1.76 | -2.37 | 1.14 | 2.08 | 1.6 | |
Working capital | 50.42M | 16.42M | 40.1M | 136.47M | 178.62M | |
Tangible asset value | -84.77M | -118.6M | 39.95M | 140.08M | 181.64M | |
Net current asset value | -90.52M | -122.75M | 38.24M | 133.43M | 176.78M | |
Invested capital | -0.17 | -0.13 | 0.23 | 0.03 | 0.02 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 1.18M | 845K | 964K | 2.12M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 108.29 | 161.09 | 194.86 | 648.34 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 3.37 | 2.27 | 1.87 | 0.56 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.45 | 0.29 | -0.74 | -0.59 | -0.2 | |
Capex per share | -0.04 | -0.01 | 0 | -0.02 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.11 | -0.1 | -0.05 | -0.09 | -0.08 | |
Operating cash flow per share | -0.11 | -0.1 | -0.1 | -0.08 | -0.05 | |
Free cash flow per share | -0.11 | -0.1 | -0.1 | -0.08 | -0.05 | |
Cash per share | 1.19 | 1.77 | 1.39 | 1.33 | 1.28 | |
Book value per share | 1.15 | 1.73 | 1.39 | 1.33 | 1.26 | |
Tangible book value per share | 1.15 | 1.73 | 1.39 | 1.33 | 1.26 | |
Share holders equity per share | 1.15 | 1.73 | 1.39 | 1.33 | 1.26 | |
Interest debt per share | 0.04 | 0.04 | 0.01 | 0.02 | 0.02 | |
Market cap | 230.3M | 529.09M | 413.25M | 403M | 251.03M | |
Enterprise value | 217.04M | 497.07M | 388.86M | 386.06M | 222.64M | |
P/E ratio | -5.07 | -12.84 | -17.33 | -8.93 | -6.3 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -21.05 | -49.72 | -33.79 | -39.85 | -42.39 | |
PFCF ratio | -21 | -49.47 | -33.79 | -39.81 | -42.32 | |
P/B Ratio | 1.98 | 2.91 | 2.36 | 2.39 | 1.57 | |
PTB ratio | 1.98 | 2.91 | 2.36 | 2.39 | 1.57 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -18.89 | -44.74 | -42.13 | -30.02 | -19.43 | |
EV to operating cash flow | -19.84 | -46.71 | -31.8 | -38.18 | -37.6 | |
EV to free cash flow | -19.79 | -46.48 | -31.8 | -38.13 | -37.53 | |
Earnings yield | -0.05 | -0.02 | -0.01 | -0.03 | -0.04 | |
Free cash flow yield | -0.05 | -0.02 | -0.03 | -0.03 | -0.02 | |
Debt to equity | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | |
Debt to assets | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 1.15 | 2.88 | 2.64 | 1.32 | 2.48 | |
Current ratio | 12.8 | 12.05 | 16.41 | 18.07 | 18.26 | |
Interest coverage | -20.22 | -9.96 | 5.18 | 0 | 0 | |
Income quality | 0.91 | 0.92 | 1.56 | 0.9 | 0.59 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.06 | -0.11 | 0 | -0.02 | -0.02 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.7 | 1.95 | 1.21 | 1.63 | 1.49 | |
ROIC | -0.1 | -0.06 | -0.04 | -0.08 | -0.07 | |
Return on tangible assets | -0.09 | -0.05 | -0.03 | -0.06 | -0.06 | |
Graham Net | 1.08 | 1.6 | 1.29 | 1.25 | 1.21 | |
Working capital | 112.98M | 178.62M | 172.41M | 165.57M | 157.46M | |
Tangible asset value | 116.12M | 181.64M | 175.27M | 168.29M | 160.05M | |
Net current asset value | 110.83M | 176.78M | 170.89M | 164.38M | 156.59M | |
Invested capital | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 4.65M | 3.07M | 2.25M | 924.5K | 1.52M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 510.25 | 628.88 | 210.5 | 137.18 | 445.36 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.18 | 0.14 | 0.43 | 0.66 | 0.2 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.1 | -0.06 | -0.03 | -0.07 | -0.06 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CMPX Frequently Asked Questions
What is Compass Therapeutics, Inc. stock symbol ?
Compass Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol CMPX
What is Compass Therapeutics, Inc. stock quote today ?
Compass Therapeutics, Inc. stock price is $2.05 today.
Is Compass Therapeutics, Inc. stock public?
Yes, Compass Therapeutics, Inc. is a publicly traded company.